Lucila Garcia-Contreras, Ph.D.

Associate Professor

Pharmaceutical Sciences

Phone (405) 271-6593 x47205

Fax (405) 271-7505

Office CPB 321

Email lucila-garcia-contreras@ouhsc.edu


Summary

The research goal of my laboratory is “Targeted Drug Delivery” and involves the rational design of dosage forms and their in vitro evaluation, which are used to design in vivo studies. In turn, the information obtained in in vitro and in vivo studies is used to understand the underlying reasons of the performance of the dosage form with the objective of improving its formulation design to achieve the desired therapeutic effect. 

   A recent project that illustrates this process is the formulation of a novel molecule with anticancer and antimicrobial activity for pulmonary delivery as nanocrystals or microparticles. In vitro evaluation included size analysis using Scanning Electron Microscopy (SEM) and laser diffraction; stability, using (Fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD) and differential scanning calorimetry (DSC). We determined the aerosol performance of these formulations using commercial dry powder inhalers and performed pharmacokinetic studies to determine the disposition of the drug after pulmonary administration to mice. Lastly, in collaboration with Dr. Jie Wu from the OUHSC Department of Pathology, we assessed the efficacy of the nanocrystals in a transgenic mouse model of adenocarcinoma.

   My laboratory also designs dosage forms for oral, vaginal and transdermal administration following same procedure.  A second line of investigation of my laboratory is the development of needle-less vaccines to provide mucosal and systemic immunization. We are interested in elucidating the role of cell mediated immune (CMI) response and humoral immunity to the overall protection provided by the vaccine. Examples of vaccines studied in my laboratory include vaccines against tuberculosis, West Nile Virus, Diphtheria and Shigellosis.



Education & Experience

Master of Science in Science

Dept. of Pharmaceutics, College of Pharmacy, Univ. of Georgia, Athens, GA.

1995

Doctor of Philosophy, in Philosophy

College of Pharmacy, Univ. of Georgia, Dept. of Pharmaceutical and Biomedical Sciences, , Athens, GA

1999

Postdoctoral Fellowship in Division of Drug Delivery and Disposition

School of Pharmacy. Univ. of North Carolina, Chapel Hill, NC

2003


Publications & Presentations

1 2 3 4 > >>
    1. Bourlon M, Garcia-Contreras L. “Optimization of particle characteristics for use in deposition studies to inform computational modeling to improve emphysema treatment”. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2021; 34 : A11

    2. Garcia-Contreras L, Sethuraman V, Kazantseva M, Hickey A J. "Efficacy of Combined Rifampicin Formulations Delivered by the Pulmonary Route to Treat Tuberculosis in the Guinea Pig Model". Pharmaceutics. 2021; 13 : 1309 - 12

    3. Chandra V, Rai R, Lightfoot S S, Hatipoglu M K, Garcia-Contreras L, Benbrook D M. Chemoprevention and regression of estrogen-induced atypical endometrial hyperplasia by oral SHetA2 in a rat model. Clinical Cancer Research . 2021; 27 : 40-40

    4. Osei N, Agrawal S, Garcia-Contreras L. Polymorphism Influences the Physicochemical Characteristics of Anti-Tuberculosis Drugs Formulated as Nanocrystals. AAPS Journal. 2020; 2020

    5. Chandra V, Rai R, Hussain S, Garcia-Contreras L, Hatipoglu M, Benbrook D M. Development of a rat model of atypical endometrial hyperplasia and a vaginal suppository formulation of SHetA2 for chemoprevention studies. Cancer Research. 2020; 80 : 27-27

1 2 3 4 > >>



Grants

1 2 3 4 >>
    1. Novel Ophthalmic Product for Corneal Infections and Injuries. NIH. Start Date: 2021. End Date: 2022.

    2. Understanding the effects of sphero-cylinder drug particle shape to enhance small-airway drug delivery for better emphysema treatment outcomes. Misc Non-Federal. Start Date: 2019. End Date: 2022.

    3. Targeting HPV Consequences in a Cervical Cancer Clinical Trial. NIH. Start Date: 2016. End Date: 2022.

    4. Preclinical Assessment of OHet72 as a new drug in the armamentarium against TB and MDR-TB. NIH. Start Date: 2019. End Date: 2021.

    5. Ovarian Cancer Chemoprevention. NIH. Start Date: 2015. End Date: 2020.

1 2 3 4 >>



Awards and Honors

                                                                                            1. University of Oklahoma Health Sciences Center. Carlisle and Lurline Mabrey Presidential Professorship. Date: 2020.  

                                                                                            2. Respiratory Drug Delivery. Posters on the podium. Date: 2012.  

                                                                                            3. Graduate Research Association of Students in Pharmaceutics Best poster presentation. Date: 1997.  

                                                                                            4. Fulbright. Fulbright-Conacyt Scholarship. Date: 1993.  

                                                                                            5. National Autonomous University of Mexico. Gabino Barreda Medal-UNAM. Date: 1991.  




Education

                                                                                            1.  Degree: Post doctoral education. the University of North Carolina at Chapel Hill. Date: 2001.  

                                                                                            2.  Degree: Ph D. The University of Georgia. Date: 1999.  

                                                                                            3.  Degree: MS. The University of Georgia. Date: 1995.  

                                                                                            4.  Degree: Chemist Pharmacist Biologist. National Autonomous University of Mexico. Date: 1991.